A study highlights insufficient standardized safety and efficacy assessments for FDA-cleared AI/ML medical devices.
Key Details
- 1Cross-sectional analysis of FDA-cleared AI/ML-enabled devices was conducted.
- 2The study found lack of standardized efficacy and safety reporting in device clearance.
- 3Suggested need for dedicated regulatory pathways and post-market AI/ML safety surveillance.
- 4Study was published in JAMA Health Forum and led by Dr. Ravi B. Parikh.
Why It Matters
As imaging AI tools increasingly enter clinical use, robust regulatory oversight is critical for patient safety and clinician trust. Gaps in FDA reporting and surveillance could impact the safe integration of AI in radiology practice.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.